With the FDA approving its ANDA application on May 26, 2026, RICONPHARMA LLC is positioned to capture significant market share by launching a generic alternative immediately. This clearance allows the company to directly challenge established competitors in the segment, driving short-term revenue growth and solidifying its presence in the industry.